WO1994004691A3 - Formes dimeres et multimeres de polypeptides monocatenaires - Google Patents
Formes dimeres et multimeres de polypeptides monocatenaires Download PDFInfo
- Publication number
- WO1994004691A3 WO1994004691A3 PCT/US1993/007918 US9307918W WO9404691A3 WO 1994004691 A3 WO1994004691 A3 WO 1994004691A3 US 9307918 W US9307918 W US 9307918W WO 9404691 A3 WO9404691 A3 WO 9404691A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- single chain
- dimer
- chain polypeptides
- antibodies
- multimers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
Abstract
L'invention concerne de nouvelles protéines constituant des dimères et des multimères d'anticorps monocaténaires. Les anticorps monocaténaires contiennent des polypeptides de deux domaines dérivés des domaines variables d'anticorps joints par une liaison peptidique. Les dimères et multimères sont formés par liaison non covalente des polypeptides monocaténaires. On peut citer parmi les emplois tous ceux appropriés à des anticorps monoclonaux et polyclonaux et des fragments de ceux-ci, y compris comme molécule de fixation d'antigène bispécifique.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU50872/93A AU5087293A (en) | 1992-08-21 | 1993-08-20 | Dimer and multimer forms of single chain polypeptides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/935,695 | 1992-08-21 | ||
US07/935,695 US6329507B1 (en) | 1992-08-21 | 1992-08-21 | Dimer and multimer forms of single chain polypeptides |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994004691A2 WO1994004691A2 (fr) | 1994-03-03 |
WO1994004691A3 true WO1994004691A3 (fr) | 1994-03-31 |
Family
ID=25467525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/007918 WO1994004691A2 (fr) | 1992-08-21 | 1993-08-20 | Formes dimeres et multimeres de polypeptides monocatenaires |
Country Status (3)
Country | Link |
---|---|
US (2) | US6329507B1 (fr) |
AU (1) | AU5087293A (fr) |
WO (1) | WO1994004691A2 (fr) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5851526A (en) * | 1985-04-19 | 1998-12-22 | Ludwig Institute For Cancer Research | Methods of treating colon cancer utilizing tumor-specific antibodies |
US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
US6027725A (en) * | 1991-11-25 | 2000-02-22 | Enzon, Inc. | Multivalent antigen-binding proteins |
AU5670194A (en) * | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
JP3720353B2 (ja) * | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
AU680685B2 (en) | 1993-09-22 | 1997-08-07 | Medical Research Council | Retargeting antibodies |
US6103521A (en) * | 1995-02-06 | 2000-08-15 | Cell Genesys, Inc. | Multispecific chimeric receptors |
AU7266898A (en) | 1997-04-30 | 1998-11-24 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
DK1039931T3 (da) * | 1997-12-01 | 2005-08-08 | Fang Fang | Multivalente rekombinante antistoffer til at behandle HRV infektioner |
US6818213B1 (en) * | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
CA2331789C (fr) * | 1998-07-13 | 2013-09-10 | Board Of Regents, The University Of Texas System | Procedes de traitement du cancer mettant en application des conjugues therapeutiques se fixant a des aminophospholipides |
EP1096955B9 (fr) * | 1998-07-13 | 2006-07-05 | Board of Regents, The University of Texas System | L'utilisation d'anticorps vis-a-vis des aminophospholipides pour le traitement du cancer |
US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
US20030035798A1 (en) * | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
WO2002007783A2 (fr) * | 2000-07-20 | 2002-01-31 | Regents Of The University Of Minnesota | Immunotoxines radiomarquees |
WO2002098917A2 (fr) * | 2001-02-12 | 2002-12-12 | Curagen Corporation | Proteines, polynucleotides codant pour lesdites proteines et methodes d'utilisation desdites proteines |
CA2444854A1 (fr) * | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Banques combinatoires de domaines monomeres |
CN1195779C (zh) * | 2001-05-24 | 2005-04-06 | 中国科学院遗传与发育生物学研究所 | 抗人卵巢癌抗人cd3双特异性抗体 |
JP2005522192A (ja) | 2001-07-19 | 2005-07-28 | パーラン セラピューティクス, インコーポレイテッド | マルチマータンパク質およびマルチマータンパク質を作製および使用する方法 |
US7653490B2 (en) * | 2001-09-10 | 2010-01-26 | Triad Liquidating Company LLC | Nuclear magnetic resonance assembly of chemical entities |
DE10148561A1 (de) * | 2001-10-01 | 2003-04-10 | Merck Patent Gmbh | Verfahren und Mittel zur Bestimmung von Gesamtsäure |
US20040067882A1 (en) * | 2001-10-22 | 2004-04-08 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
KR100450864B1 (ko) * | 2001-11-23 | 2004-10-01 | 한국과학기술연구원 | Rna 표적 분자에 대해 특이성이 향상된네오마이신-클로람페니콜 헤테로 이합체 및 그의 제조방법 |
US7378386B2 (en) | 2002-07-15 | 2008-05-27 | Board Of Regents, The University Of Texas System | Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives |
CN1856324A (zh) * | 2002-09-17 | 2006-11-01 | Gtc生物治疗学公司 | 缺乏重链间二硫键的免疫球蛋白分子的分离 |
US7700097B2 (en) * | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
WO2006074399A2 (fr) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Molecules de liaison multispecifiques comprenant des peptides de connexion |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
JP5953303B2 (ja) | 2010-07-29 | 2016-07-20 | ゼンコア インコーポレイテッド | 改変された等電点を有する抗体 |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
AU2014205086B2 (en) | 2013-01-14 | 2019-04-18 | Xencor, Inc. | Novel heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
EP2945969A1 (fr) | 2013-01-15 | 2015-11-25 | Xencor, Inc. | Elimination rapide de complexes antigéniques à l'aide de nouveaux anticorps |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
EP3421495A3 (fr) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation de cellules t avec des anticorps bispécifiques et des fusions fc |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
EP3954713A3 (fr) | 2014-03-28 | 2022-03-30 | Xencor, Inc. | Anticorps bispécifiques se liant à cd38 et cd3 |
WO2016043577A1 (fr) | 2014-09-16 | 2016-03-24 | Academisch Medisch Centrum | Molécules de type ig se liant à la bmp4 |
CA2967426A1 (fr) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Anticorps heterodimeriques se liant a l'antigene cd3 et a un antigene tumoral |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
BR112017011166A2 (pt) | 2014-11-26 | 2018-02-27 | Xencor, Inc. | anticorpos heterodiméricos que se ligam a cd3 e cd38 |
WO2016105450A2 (fr) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Anticorps trispécifiques |
JP6444486B2 (ja) | 2015-02-05 | 2018-12-26 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | 志賀毒素aサブユニットエフェクター領域を含む多価cd20結合分子及びそれらの強化組成物 |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
EP3387013B1 (fr) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Anticorps hétérodimères se liant à cd3 et psma |
MX2018015592A (es) | 2016-06-14 | 2019-04-24 | Xencor Inc | Anticuerpos inhibidores de puntos de control biespecificos. |
CA3029328A1 (fr) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Anticorps heterodimeriques qui se lient au recepteur 2 de la somatostatine |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
AU2017342559B2 (en) | 2016-10-14 | 2022-03-24 | Xencor, Inc. | Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments |
WO2018140427A1 (fr) | 2017-01-25 | 2018-08-02 | Molecular Templates, Inc. | Molécules de ciblage de cellules comprenant des effecteurs de sous-unité de shiga-toxines a et des épitopes de lymphocytes t cd8+ |
JP2020529832A (ja) | 2017-06-30 | 2020-10-15 | ゼンコア インコーポレイテッド | IL−15/IL−15Rαおよび抗原結合ドメインを含む標的化ヘテロダイマーFc融合タンパク質 |
EP3706793A1 (fr) | 2017-11-08 | 2020-09-16 | Xencor, Inc. | Anticorps bispécifiques et monospécifiques utilisant de nouvelles séquences anti-pd-1 |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
WO2019125732A1 (fr) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Protéines de fusion il-2 fc modifiées |
AU2019247415A1 (en) | 2018-04-04 | 2020-10-22 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
AU2019256529A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains |
CA3097593A1 (fr) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Proteines de fusion heterodimeres ciblant pd-1 contenant des proteines de fusion fc d'il-15/il-15ra, domaines de liaison a l'antigene pd-1 et utilisations associees |
JP2022503959A (ja) | 2018-10-03 | 2022-01-12 | ゼンコア インコーポレイテッド | Il-12ヘテロ二量体fc-融合タンパク質 |
WO2020180726A1 (fr) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Anticorps hétérodimères qui se lient à enpp3 et cd3 |
WO2021102445A1 (fr) | 2019-11-24 | 2021-05-27 | Molecular Templates, Inc. | Utilisations de molécules de liaison à cd20 et d'agents thérapeutiques supplémentaires |
WO2021231976A1 (fr) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3 |
EP4305067A1 (fr) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Anticorps hétérodimériques se liant à cd3 et à cldn6 |
WO2022192586A1 (fr) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Anticorps hétérodimères qui se lient au cd3 et au gpc3 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO1991019739A1 (fr) * | 1990-06-11 | 1991-12-26 | Celltech Limited | Proteines polyvalentes de liaison d'antigenes |
EP0506124A1 (fr) * | 1991-03-27 | 1992-09-30 | Tanox Biosystems, Inc. | Méthodes et produits pour diriger des agents thérapeutiques vers des tissus solides comprenant deux molécules de liaison bifonctionnelles VH-VL monocaténaires |
WO1993011161A1 (fr) * | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Proteines multivalentes de fixation aux antigenes |
WO1993012231A1 (fr) * | 1991-12-13 | 1993-06-24 | Dow Chemical (Australia) Limited | Composites de la chaine legere du sous-groupe humain iv aptes a la liaison avec tag-72 |
WO1993015210A1 (fr) * | 1992-01-23 | 1993-08-05 | Merck Patent Gmbh | Proteines fusionnees monomeres et dimeres a fragments d'anticorps |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
ATE64618T1 (de) | 1982-03-15 | 1991-07-15 | Schering Corp | Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer. |
US5001225A (en) * | 1986-12-08 | 1991-03-19 | Georgetown University | Monoclonal antibodies to a pan-malarial antigen |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
ATE120761T1 (de) * | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US5130297A (en) | 1988-06-23 | 1992-07-14 | Anergen, Inc. | Conjugates useful in ameliorating autoimmunity MHC-II-peptide |
-
1992
- 1992-08-21 US US07/935,695 patent/US6329507B1/en not_active Expired - Lifetime
-
1993
- 1993-08-20 WO PCT/US1993/007918 patent/WO1994004691A2/fr active Application Filing
- 1993-08-20 AU AU50872/93A patent/AU5087293A/en not_active Abandoned
-
1995
- 1995-06-05 US US08/463,903 patent/US6071515A/en not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO1991019739A1 (fr) * | 1990-06-11 | 1991-12-26 | Celltech Limited | Proteines polyvalentes de liaison d'antigenes |
EP0506124A1 (fr) * | 1991-03-27 | 1992-09-30 | Tanox Biosystems, Inc. | Méthodes et produits pour diriger des agents thérapeutiques vers des tissus solides comprenant deux molécules de liaison bifonctionnelles VH-VL monocaténaires |
WO1993011161A1 (fr) * | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Proteines multivalentes de fixation aux antigenes |
WO1993012231A1 (fr) * | 1991-12-13 | 1993-06-24 | Dow Chemical (Australia) Limited | Composites de la chaine legere du sous-groupe humain iv aptes a la liaison avec tag-72 |
WO1993015210A1 (fr) * | 1992-01-23 | 1993-08-05 | Merck Patent Gmbh | Proteines fusionnees monomeres et dimeres a fragments d'anticorps |
Also Published As
Publication number | Publication date |
---|---|
US6071515A (en) | 2000-06-06 |
WO1994004691A2 (fr) | 1994-03-03 |
AU5087293A (en) | 1994-03-15 |
US6329507B1 (en) | 2001-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994004691A3 (fr) | Formes dimeres et multimeres de polypeptides monocatenaires | |
Kriangkum et al. | Bispecific and bifunctional single chain recombinant antibodies | |
CA2149120A1 (fr) | Anticorps monoclonal se liant specifiquement a l'endothelium vasculaire tumoral et utilisations de cette substance | |
CY1121451T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα κατα του ctla-4 | |
CY1107708T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης | |
WO2002008293A3 (fr) | Proteine de liaison cible multivalente | |
HUT65687A (en) | Humanized and chimaeric monoclonal antibodies comprising of them pharmaceutical composition and the antibodies coding sequence containing of expression vectors, and process for the praparation of antibodies | |
ES2173130T3 (es) | Metodo de fijacion de material al peptido beta-amiloide. | |
CA2328851A1 (fr) | Immunoglobulines humaines; leurs productions et utilisations | |
NO942912L (no) | Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5 | |
EE9900492A (et) | II tüüpi TGF-ß retseptori/immunoglobuliini konstantse piirkonna hübriidvalgud | |
CA2501818A1 (fr) | Compositions pharmaceutiques relatives a des recepteurs de erb-b1 | |
WO2001090192A3 (fr) | Proteines bispecifiques de liaison a l'antigene du type immunoglobulines, et procede de production correspondant | |
UA89017C2 (uk) | ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b | |
DE69726003D1 (de) | Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit | |
KR960704576A (ko) | CD40에 대한 항체(Antibodies to CD40) | |
DK677688D0 (da) | Humane somatomedinbaererproteinunderenheder og fremgangsmaade til fremstilling af saadanne | |
DE59309458D1 (de) | Synthetische Peptide, Antikörper dagegen und ihre Verwendung | |
Lu et al. | Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2 | |
EP1350799A3 (fr) | Polypeptides d'immunoglobulines inhibiteurs se liant au récepteur-beta humain de PDGF | |
EP1396539A4 (fr) | Anticorps contre le facteur viii de coagulation sanguine de type humain | |
FI20095269A (fi) | Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli | |
Mizutani et al. | Effector functions of a mouse IgG that lacks the entire CH1 domain. C1q binding and complement fixation in the absence of antigen. | |
HUP0003029A2 (hu) | Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BR CA HU JP KR NO NZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BR CA HU JP KR NO NZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |